-
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease
Latest News
-
Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin
⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.
-
Safety trials add crucial piece to gene silencing jigsaw
Three trials of drugs to 'silence' the HD gene in monkeys show they hit the target safely. Human trials coming soon.
-
Melatonin treatment success in HD mice
Melatonin delays disease onset and extends survival in Huntington's disease mice – could it do the same for patients?
-
HD World Congress 2011: a retrospective
HDBuzz looks back at the highlights of the Huntington's disease world congress 2011 in Melbourne
-
HDAC inhibitors and a possible 'blood biomarker'
HDAC inhibitors explained, plus how new HDAC-related Huntington's disease research might help us find biomarkers
-
HD just got cilia
Huntington's disease just got cilia: huntingtin protein affects tiny but important hairs on cells called cilia
-
Gene silencing takes a targeted step forward
Targeting the mutant Huntington's disease gene for silencing, while leaving the healthy gene untouched
-
Prana Biotech's new trial of PBT2 in Huntington's disease: the lowdown
Prana Biotech's PBT2 trial in Huntington's disease: what we know so far & what copper has to do with the mutant prote
-
Oz Buzz Video: Day 2
The final day of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
-
Oz Buzz Video: Day 1
Day 1 of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
-
Oz Buzz Updates: Day 3
Day 3 of our coverage of the Huntington's disease World Congress 2011 in Melbourne
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
